These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14749543)

  • 1. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C.
    Maeda Y; Kiribayashi Y; Moriya T; Maruhashi A; Omoda K; Funakoshi S; Murakami T; Takano M
    Ther Drug Monit; 2004 Feb; 26(1):9-15. PubMed ID: 14749543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.
    Jen JF; Glue P; Gupta S; Zambas D; Hajian G
    Ther Drug Monit; 2000 Oct; 22(5):555-65. PubMed ID: 11034261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.
    Bruchfeld A; Lindahl K; Schvarcz R; Ståhle L
    Ther Drug Monit; 2002 Dec; 24(6):701-8. PubMed ID: 12451285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T; Honda T; Hayashi K; Katano Y; Goto H
    J Viral Hepat; 2008 Sep; 15(9):651-8. PubMed ID: 18637076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function.
    Kamar N; Chatelut E; Manolis E; Lafont T; Izopet J; Rostaing L
    Am J Kidney Dis; 2004 Jan; 43(1):140-6. PubMed ID: 14712437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
    Jain AB; Eghtesad B; Venkataramanan R; Fontes PA; Kashyap R; Dvorchik I; Shakil AO; Kingery L; Fung JJ
    Liver Transpl; 2002 Nov; 8(11):1007-13. PubMed ID: 12424713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
    de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
    J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.
    Tod M; Farcy-Afif M; Stocco J; Boyer N; Bouton V; Sinègre M; Marcellin P
    Clin Pharmacokinet; 2005; 44(4):417-28. PubMed ID: 15828854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
    Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
    Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
    Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
    J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
    González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
    Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response.
    Furusyo N; Murata M; Ogawa E; Toyoda K; Ihara T; Ikezaki H; Hayashi T; Koga T; Kainuma M; Hayashi J
    J Antimicrob Chemother; 2011 May; 66(5):1127-39. PubMed ID: 21393126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
    Tromm A; Greving I; Griga T; Mankel K; Hüppe D
    Z Gastroenterol; 2000 Feb; 38(2):159-64. PubMed ID: 10721171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
    Khakoo S; Glue P; Grellier L; Wells B; Bell A; Dash C; Murray-Lyon I; Lypnyj D; Flannery B; Walters K; Dusheiko GM
    Br J Clin Pharmacol; 1998 Dec; 46(6):563-70. PubMed ID: 9862245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors contributing to ribavirin-induced anemia.
    Nomura H; Tanimoto H; Kajiwara E; Shimono J; Maruyama T; Yamashita N; Nagano M; Higashi M; Mukai T; Matsui Y; Hayashi J; Kashiwagi S; Ishibashi H
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1312-7. PubMed ID: 15482540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection.
    Tsubota A; Hirose Y; Izumi N; Kumada H
    Br J Clin Pharmacol; 2003 Apr; 55(4):360-7. PubMed ID: 12680884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.
    Rower JE; Meissner EG; Jimmerson LC; Osinusi A; Sims Z; Petersen T; Bushman LR; Wolfe P; McHutchison JG; Kottilil S; Kiser JJ
    J Antimicrob Chemother; 2015 Aug; 70(8):2322-9. PubMed ID: 25971261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
    Pedersen C; Alsiö Å; Lagging M; Langeland N; Färkkilä M; Buhl MR; Mørch K; Westin J; Sangfelt P; Norkrans G; Christensen PB;
    J Viral Hepat; 2011 Apr; 18(4):245-51. PubMed ID: 20384961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.